Onkologie. 2013:7(2):83-87 [Urol. praxi, 2013; 14(2): 63-66]

Non-surgical treatment of metastatic renal cell carcinoma

Milada Zemanová

Onkologická klinika 1. LF UK a VFN, Katedra klinické onkologie IPVZ Praha

The treatment of advanced and metastatic renal cell cancer is based on systemic therapy in combination with cytoreductive local

approaches. Cytokines, used in the past, may currently be beneficial for patients in a good prognostic group, but molecularly targeted

biological treatment, mainly directed at key points of the defective VHL/HIF pathway, showed significantly better efficacy in patients of

all prognostic groups with prolonged survival compared to interferon alpha. Currently tyrosinekinase receptor inhibitors for angiogenic

growth factors, sorafenib, sunitinib and pazopanib, monoclonal antibody neutralizing vascular endothelial growth factor bevacizumab

and mTOR kinase inhibitors temsirolimus and everolimus are registered for the first or second-line treatment of advanced and/or metastatic

disease. Axitinib, 2nd generation tyrosinkinase inhibitor is expected to be register.

Keywords: renal cell carcinoma, sorafenib, sunitinib, bevacizumab, pazopanib, everolimus, axitinib

Published: May 1, 2013  Show citation